Govt unable to cut anti-cancer drug price
NEW DELHI: Government’s efforts to reduce prices of anti-cancer drugs seem to have fallen flat. It had recently asked leading manufacturers to come up with proposals for making cancer drugs more affordable, including reducing their margins to the minimum.
On its part, government proposed to exempt cancer drugs from all taxes (excise and import duties). But, their efforts have come to a naught.
Industry experts said prices of these drugs are so high that the reduction in duties or state levies hardly makes a difference.
Even if industry reduces its margins, the impact would be insignificant. Take the case of Eli Lilly’s Gemcite used for the treatment of lung cancer. With a MRP of Rs 8,000 per vial, the cost of the treatment with this drug comes to around Rs 1 lakh plus.
SOURCE:THE TIMES OF INDIA
THE Income-Tax Department conducted search operations in two major pharmaceutical companies and a bakery chain. The pharma majors are Cipla Read more
INCOME-TAX authorities today raided the premises of Great Eastern Shipping Company, Ipca Laboratories and RNA Builders. Altogether, 40 premises have Read more
LONDON: A Non-Resident Indian plastic surgeon, who falsely claimed that his sister and uncle were killed in the September 11 Read more
NEW DELHI: San Francisco-based Farallon Capital Management, L.L.C. has invested Rs 88 crore for 33.3% stake in Indiabulls Credit Services Read more
